192 related articles for article (PubMed ID: 3862071)
41. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
Schwartz EL; Brown BJ; Nierenburg M; Marsh JC; Sartorelli AC
Cancer Res; 1983 Jun; 43(6):2725-30. PubMed ID: 6573951
[TBL] [Abstract][Full Text] [Related]
42. In vitro sensitivity of myeloblast clonogenic cells to doxorubicin, aclacinomycin A, and 4'-O-tetrapyranyl-doxorubicin: correlations with clinical responses.
Georgoulias V; Iskandar YL; Amesland F; Ribaud P; Mathé G; Jasmin C
J Clin Oncol; 1984 Nov; 2(11):1215-22. PubMed ID: 6593437
[TBL] [Abstract][Full Text] [Related]
43. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
[TBL] [Abstract][Full Text] [Related]
44. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
45. Anthracyclines in the treatment of acute nonlymphocytic leukemias.
Boiron M; Jacquillat C; Marty M; Weil M; Gisselbrecht C
Cancer Treat Rep; 1981; 65 Suppl 4():73-6. PubMed ID: 6955013
[No Abstract] [Full Text] [Related]
46. Clinical studies of aclacinomycin A (ACM).
Majima H; Ohta K
Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
[TBL] [Abstract][Full Text] [Related]
47. Agar culture of bone marrow cells in acute myeloid leukemia and dysmyelopoietic syndromes. Reevaluation of its prognostic value.
Coiffier B; Bryon PA; Fière D; Felman P; Gentilhomme O; Vu Van H; Viala JJ; Germain D
Nouv Rev Fr Hematol (1978); 1982; 24(1):13-8. PubMed ID: 6951141
[TBL] [Abstract][Full Text] [Related]
48. A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.
Schölzel C; van Putten W; Löwenberg B
Leuk Res; 1986; 10(12):1455-9. PubMed ID: 3467144
[TBL] [Abstract][Full Text] [Related]
49. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.
Herman EH; Young RS
Cancer Treat Rep; 1979; 63(11-12):1771-9. PubMed ID: 526912
[TBL] [Abstract][Full Text] [Related]
50. [Sudden death in leukemic patients treated with doxorubicin].
Lacasse Y; Bolduc P
Can J Cardiol; 1992; 8(1):53-6. PubMed ID: 1617512
[TBL] [Abstract][Full Text] [Related]
51. Treatment of murine myeloid leukemia by aclacinomycin-A based on the dynamics of leukemic colony forming unit and normal hematopoietic stem cells.
Nara N
Nihon Ketsueki Gakkai Zasshi; 1982 Dec; 45(7):1324-32. PubMed ID: 6963084
[No Abstract] [Full Text] [Related]
52. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.
Alberts DS; Van Daalen Wetters T
Br J Cancer; 1976 Jul; 34(1):64-8. PubMed ID: 952715
[TBL] [Abstract][Full Text] [Related]
53. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
Warrell RP
Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
[TBL] [Abstract][Full Text] [Related]
54. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
55. Mutagenicity of eight anthracycline derivatives in five strains of Salmonella typhimurium.
Marzin D; Jasmin C; Maral R; Mathe G
Eur J Cancer Clin Oncol; 1983 May; 19(5):641-7. PubMed ID: 6347692
[TBL] [Abstract][Full Text] [Related]
56. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
[TBL] [Abstract][Full Text] [Related]
57. [Role of cell pharmacokinetics in the modulation of modalities in the administration of anthracyclines].
Tapiéro H; Boule D; Trincal G; Fourcade A
Pathol Biol (Paris); 1987 Jan; 35(1):20-6. PubMed ID: 3550608
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of mitoxantrone in acute leukemia.
Masaoka T; Shibata H; Oguma S; Nagai K; Kitani T; Horiuchi A; Yasunaga K; Yonezawa T; Kawagoe H
Invest New Drugs; 1985; 3(2):197-201. PubMed ID: 3860489
[TBL] [Abstract][Full Text] [Related]
59. A statistical model for in-vitro assessment of patient sensitivity to cytotoxic drugs.
Minkin S
Biometrics; 1991 Dec; 47(4):1581-91. PubMed ID: 1786331
[TBL] [Abstract][Full Text] [Related]
60. In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.
Klumper E; Pieters R; den Boer ML; Huismans DR; Loonen AH; Veerman AJ
Br J Cancer; 1995 Jun; 71(6):1188-93. PubMed ID: 7779709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
